ARYA Atherosclerosis Journal

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Thyroid dysfunction in heart failure with preserved ejection fraction: A systematic review and meta-analysis

Document Type : Review Article

Authors

1 Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

4 Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Community and Preventive Medicine Department, Medicine Faculty, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

BACKGROUND: Despite controversial findings regarding the association between thyroid hormones and heart failure with preserved ejection fraction (HFpEF), thyroid dysfunction is widely assumed to be independently associated with this condition. Herein, we sought to systematically review the existing literature and estimate the prevalence of thyroid dysfunction in patients with HFpEF.
METHODS: We conducted a comprehensive search in PubMed, Scopus, Web of Science, Embase, and ProQuest up to the end of November 2024. Observational studies assessing thyroid dysfunction prevalence in patients with HFpEF were included in this study. The prevalence of overt thyroid dysfunction, low T3 syndrome, and subclinical hypothyroidism (SCH) was pooled using a random-effects model. Duval and Tweedie’s Trim and Fill test, funnel plot, and Egger’s test were utilized for publication bias assessment. All analyses were conducted with R Version 4.5.1 and Comprehensive Meta-Analysis Version 3 software.
RESULTS: Fourteen studies involving 3,931 subjects with HFpEF were included in this analysis. The pooled prevalence of overt thyroid dysfunction, based on six studies, was 15% (95% CI: 7%–29%). The pooled prevalence of low T3 syndrome was 22% (95% CI: 20%–25%), and for SCH, it was 15% (95% CI: 1%–68%).
CONCLUSION: Despite heterogeneity among the included studies, our findings suggest that thyroid dysfunction is relatively common in patients with HFpEF and may be associated with more severe symptoms and worse outcomes.

Keywords

References
1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-87. https://doi.org/10.1093/cvr/cvac013
2. Namvar M, Fakhrolmobasheri M, Mazaheri-Tehrani S, Heidarpour M, Emamimeybodi M, Shafie D. Association between the Length of Hospital Stay and 30-Day Outcomes in Patients Admitted with Acute Decompensated Heart Failure. Emerg Med Int. 2023 Mar 6;2023:6338597. https://doi.org/10.1155/2023/6338597
3. Rabiee Rad M, Ghasempour Dabaghi G, Sadri H, Darouei B, Amani-Beni R, Mazaheri-Tehrani S. Triglyceride glucose-waist circumference as a predictor of mortality and subtypes of cardiovascular disease: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025 Feb 15;17(1):59. https://doi.org/10.1186/s13098-025-01616-9
4. Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019;124:1598–617. https://doi.org/10.1161/CIRCRESAHA.119.313572
5. Gard E, Nanayakkara S, Kaye D, Gibbs H. Management of heart failure with preserved ejection fraction. Aust Prescr. 2020;43:12–7. https://doi.org/10.18773/austprescr.2020.006
6. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. Circ Heart Fail. 2017;10:e003875. https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875
7. van Heerebeek L, Paulus WJ. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J. 2016;24:227–36. https://doi.org/10.1007/s12471-016-0810-1
8. Yamakawa H, Kato TS, Noh JY, Yuasa S, Kawamura A, Fukuda K, et al. Thyroid hormone plays an important role in cardiac function: from bench to bedside. Front Physiol. 2021;12:606931. https://doi.org/10.3389/fphys.2021.606931
9. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301–16. https://doi.org/10.1038/nrendo.2018.18
10. Shekarian A, Fakhrolmobasheri M, Mazaheri-Tehrani S, Yousefian A, Heidarpour M. The prevalence of positive thyroid autoantibodies in patients with subacute thyroiditis: a systematic review and meta-analysis. Endocrine. 2024;84:29–41. https://doi.org/10.1007/s12020-023-03655-6
11. Selvaraj S, Klein I, Danzi S, Akhter N, Bonow RO, Shah SJ. Association of Serum Triiodothyronine With B-Type Natriuretic Peptide and Severe Left Ventricular Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2012;110:234–9. https://doi.org/10.1016/j.amjcard.2012.02.068
12. Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132-9. https://doi.org/10.1016/j.ijcard.2018.04.001
13. Khatiwada S, Boro H, Farooqui FA, Alam S. Endocrine causes of heart failure: A clinical primer for cardiologists. Indian Heart J. 2021;73:14-21. https://doi.org/10.1016/j.ihj.2020.11.003
14. Tafarshiku R, Henein MY, Berisha-Muharremi V, Bytyçi I, Ibrahimi P, Poniku A, et al. Left Ventricular Diastolic and Systolic Functions in Patients with Hypothyroidism. Medicina (Mex). 2020;56:524. https://doi.org/10.3390/medicina56100524
15. Li H, Zeng R, Liao Y, Fu M, Zhang H, Wang L, et al. Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Patients With Hyperthyroidism. Front Endocrinol (Lausanne). 2021 Jan 8;11:605712. https://doi.org/10.3389/fendo.2020.605712
16. Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. Circulation. 2017 Nov 28;136(22):2100-16. https://doi.org/10.1161/CIRCULATIONAHA.117.028753
17. Yan Y, Xu M, Wu M, Wang X, Li F, Zhang J, et al. Obesity is associated with subclinical hypothyroidism in the presence of thyroid autoantibodies: a cross-sectional study. BMC Endocr Disord. 2022;22:94. https://doi.org/10.1186/s12902-022-00981-0
18. Cai Y, Ren Y, Shi J. Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of cross-sectional data. Hypertens Res. 2011;34:1098-105. https://doi.org/10.1038/hr.2011.91
19. Kinugasa Y, Yamamoto K. Subclinical hypothyroidism as a new therapeutic target for patients with heart failure with preserved ejection fraction. Circ J Off J Jpn Circ Soc. 2014;78:1333-4. https://doi.org/10.1253/circj.cj-14-0436
20. Neves JS, Vale C, von Hafe M, Borges-Canha M, Leite AR, Almeida-Coelho J, et al. Thyroid hormones and modulation of diastolic function: a promising target for heart failure with preserved ejection fraction. Ther Adv Endocrinol Metab. 2020 Oct 4;11:2042018820958331. https://doi.org/10.1177/2042018820958331
21. Shekarian A, Mazaheri-Tehrani S, Shekarian S, Pourbazargan M, Setudeh M, Abhari AP, et al. Prevalence of subclinical hypothyroidism in polycystic ovary syndrome and its impact on insulin resistance: a systematic review and meta-analysis. BMC Endocr Disord. 2025;25:75. https://doi.org/10.1186/s12902-025-01896-2
22. Inciardi RM, Chandra A, Claggett B, Wijkman M, Selvin E, Kottgen A, et al. Thyroid dysfunction and incident heart failure phenotypes among older adults: the atherosclerosis risk in communities (aric) study. Eur Heart J. 2020;41 Supplement_2:ehaa946.0866. https://doi.org/10.1093/ehjci/ehaa946.0866
23. Saad M, Lacoste AG, Balar P, Zhang A, Vittorio TJ. The subclinical hypothyroid state might predict 30-day readmission in patients admitted with acute heart failure syndrome and reduced left ventricular ejection fraction. Ther Adv Cardiovasc Dis. 2020;14:1753944720977742. https://doi.org/10.1177/1753944720977742
24. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019.
25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
26. JBI Manual for Evidence Synthesis - JBI Global Wiki. https://jbi-global-wiki.refined.site/space/MANUAL. Accessed 9 Mar 2023.
27. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015 Sep;13(3):147-53. https://doi.org/10.1097/xeb.0000000000000054
28. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs Inst Rev Man Joanna Briggs Inst. 2017;5.
29. Agrawal BK, Aggarwal G, Gahlawat R, Prasad S, Saini A, Kaur B, et al. A Profile of Heart Failure with Preserved Ejection Fraction in a Teaching Hospital. Bangladesh J Med Sci. 2021;20:39-44. https://doi.org/10.3329/bjms.v20i1.50343
30. Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens MTHM, Weerts J, Spanjers MHA, et al. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. Esc Heart Fail. 2021;8:1304–13. https://doi.org/10.1002/ehf2.13204
31. Farah Yusuf Mohamud M, Jeele MOO, Cetinkaya O, Goitom Sereke S, Bongomin F, AM Ahmed M. Baseline Characteristics, Risk Factors and Etiology of Heart Failure Among Patients Hospitalized at a Teaching Hospital in Somalia: Cross-Sectional Study. Res Rep Clin Cardiol. 2022;13:63-71. https://doi.org/10.2147/RRCC.S380136
32. Favuzzi AMR, Venuti A, Bruno C, Nicolazzi MA, Fuorlo M, Dajko M, et al. Hormonal deficiencies in heart failure with preserved ejection fraction: prevalence and impact on diastolic dysfunction: a pilot study. Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):352-61. https://doi.org/10.26355/eurrev_202001_19933
33. Hassan A, Altamiranoufion A, Mahmoud S, Villines D, Mendyuk H, Klein L. Association between Subclinical Hypothyroidism and Cardiovascular Mortality in Patients Suffered from Heart Failure with Preserved Ejection Fraction. J Cardiobiol. 2016;4(1):1-4.
34. Meng Y, Zhao T, Zhang ZY, Zhang DK. Association between sub-clinical hypothyroidism and heart failure with preserved ejection fraction. Chin Med J (Engl). 2020 Feb 5;133(3):364-6. https://doi.org/10.1097/CM9.0000000000000631
35. Mfeukeu-Kuate L, Yemele HK, Jingi AM, Etoa M, Nkeck JR, Boombhi J, et al. Burden, Type, and Associated Factors of Thyroid Dysfunction in Patients with Heart Failure in Sub-Saharan Africa: A Cross-Sectional Study. World J Cardiovasc Dis. 2021;11:485-97. https://doi.org/10.4236/wjcd.2021.1111046
36. Mohamud MA, İbrahim İG, Ahmed SA, Karataş M, Jeele MOO. Prevalence of Thyroid Dysfunction Among Patients with Heart Failure at a Tertiary Hospital in Mogadishu, Somalia. Int J Gen Med. 2022 Jul 28;15:6335-9. https://doi.org/10.2147/ijgm.s371697
37. Salzano A, Marra AM, Ferrara F, Arcopinto M, Bobbio E, Valente P, et al. Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction. Int J Cardiol. 2016 Dec 15;225:1-3. https://doi.org/10.1016/j.ijcard.2016.09.085
38. Sato Y, Yoshihisa A, Kimishima Y, Kiko T, Kanno Y, Yokokawa T, et al. Low T3 Syndrome Is Associated With High Mortality in Hospitalized Patients With Heart Failure. J Card Fail. 2019 Mar;25(3):195-203. https://doi.org/10.1016/j.cardfail.2019.01.007
39. Rywik TM, Doryńska A, Wiśniewska A, Cegłowska U, Drohomirecka A, Topór-Mądry R, et al. Epidemiology and clinical characteristics of hospitalized patients with heart failure with reduced, mildly reduced, and preserved ejection fraction. Pol Arch Intern Med. 2022 May 30;132(5):16227. https://doi.org/10.20452/pamw.16227
40. Amanai S, Harada T, Kagami K, Yoshida K, Kato T, Wada N, et al. The H2FPEF and HFA-PEFF algorithms for predicting exercise intolerance and abnormal hemodynamics in heart failure with preserved ejection fraction. Sci Rep. 2022 Jan 7;12(1):13. https://doi.org/10.1038/s41598-021-03974-6
41. Sun Y, Wang N, Li X, Zhang Y, Yang J, Tse G, et al. Predictive value of H2FPEF score in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8:1244-52. https://doi.org/10.1002/ehf2.13187
42. Tao Y, Wang W, Zhu J, You T, Li Y, Zhou X. H2FPEF score predicts 1-year rehospitalisation of patients with heart failure with preserved ejection fraction. Postgrad Med J. 2021 Mar;97(1145):164-7. https://doi.org/10.1136/postgradmedj-2019-137434
43. Flamant F, Gauthier K. Thyroid hormone receptors: the challenge of elucidating isotype-specific functions and cell-specific response. Biochim Biophys Acta. 2013 Jul;1830(7):3900-7. https://doi.org/10.1016/j.bbagen.2012.06.003
44. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012 Sep;122(9):3035-43. https://doi.org/10.1172/jci60047
45. von Hafe M, Neves JS, Vale C, Borges-Canha M, Leite-Moreira A. The impact of thyroid hormone dysfunction on ischemic heart disease. Endocr Connect. 2019 May 1;8(5):R76-90. https://doi.org/10.1530/ec-19-0096
46. Marín-García J. Thyroid hormone and myocardial mitochondrial biogenesis. Vascul Pharmacol. 2010 Mar-Apr;52(3-4):120-30. https://doi.org/10.1016/j.vph.2009.10.008
47. Berta E, Lengyel I, Halmi S, Zrínyi M, Erdei A, Harangi M, et al. Hypertension in Thyroid Disorders. Front Endocrinol (Lausanne). 2019 Jul 17;10:482. https://doi.org/10.3389/fendo.2019.00482
48. Marvisi M, Balzarini L, Mancini C, Mouzakiti P. Thyroid gland and pulmonary hypertension. What’s the link? Panminerva Med. 2013 Mar;55(1):93-7.
49. Kositanurit W, Kittipibul V, Srichomkwun P, Boonyaratavej S, Puwanant S. Clinical phenotypes and prognosis of thyrotoxic heart failure and cardiomyopathy in patients hospitalized for acute heart failure. ESC Heart Fail. 2021 Aug;8(4):2776-83. https://doi.org/10.1002/ehf2.13347
50. Shojaeifard M, Davoudi Z, Erfanifar A, Fattahi Neisiani H, Erami S, Bakhshandeh H, et al. Evaluation of diastolic function in newly diagnosed hyperthyroid patients with preserved left ventricular systolic function. Cardiovasc Endocrinol Metab. 2020 Nov 19;10(3):186-90. https://doi.org/10.1097/xce.0000000000000238
51. Goldman S, McCarren M, Morkin E, Ladenson PW, Edson R, Warren S, et al. DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation. 2009 Jun 23;119(24):3093-100. https://doi.org/10.1161/circulationaha.108.834424
ARYA Atherosclerosis Journal
Volume 21, Issue 6
November and December 2025
Pages 80-98
Files
Share
How to cite
Statistics